Search Videos by Topic or Participant
Browse by Series:

Best Practices in NSCLC Molecular Testing, Part II

Panelists: David R. Gandara, MD, UC Davis; Corey J. Langer, MD, Penn Medicine; Alan B. Sandler, MD, OHSU; Mark A. Socinski, MD, University of Pitt
Published: Friday, Jan 25, 2013
For High-Definition, Click
David Gandara, MD, begins the conversation by asking a question about the timing of treatment in relation to diagnosis.

Alan B. Sandler, MD, states that while deciding on a treatment early on is important, he also sticks to the idea to refrain from ordering a test until he plans on doing something with the information. Depending on the likelihood of positive results, Sandler can adjust the plan.

In some cases, Corey J. Langer, MD, says, such as in node positive patients who have undergone definitive resection and have plans for resection, exceptions can be made. Certain tests can take multiple weeks to deliver results.

Gandara concludes the conversation by mentioning a new program led by Alliance and the National Cancer Institute where 8,000 early stage patients will undergo molecular testing for trials and their information will be available for later use.

View Part I of the discussion
Slider Left
Slider Right
For High-Definition, Click
David Gandara, MD, begins the conversation by asking a question about the timing of treatment in relation to diagnosis.

Alan B. Sandler, MD, states that while deciding on a treatment early on is important, he also sticks to the idea to refrain from ordering a test until he plans on doing something with the information. Depending on the likelihood of positive results, Sandler can adjust the plan.

In some cases, Corey J. Langer, MD, says, such as in node positive patients who have undergone definitive resection and have plans for resection, exceptions can be made. Certain tests can take multiple weeks to deliver results.

Gandara concludes the conversation by mentioning a new program led by Alliance and the National Cancer Institute where 8,000 early stage patients will undergo molecular testing for trials and their information will be available for later use.

View Part I of the discussion
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x